Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

No­var­tis to buy Mor­phoSys for $2.9B af­ter 20 years of cre­at­ing an­ti­bod­ies with the Ger­man biotech

No­var­tis inked a deal to buy Mor­phoSys for $2.9 bil­lion, in a move that gives the Swiss Big Phar­ma a can­cer drug on the verge …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.